Reshma Singh
Executive Director - Translational Science Lead, Immunology Cell Therapy AstraZeneca
Seminars
Thursday 26th March 2026
Panel Discussion: Making Cell Therapy for Autoimmunity an Off-the-Shelf Treatment Through the Advancement of Allogeneic & In Vivo Cell Therapies
11:00 am
Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:
- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy
Tuesday 24th March 2026
Afternoon Session
1:00 pm
Advancing Clinical Biomarkers for Immune Reset to Definitively Characterize the B-Cell Repertoire & Success of Cell Therapies & T-Cell Engagers
Join this workshop to explore how immune resetting is being measured in the clinic:
- Assessment of B-cell reset in peripheral blood and tissue biopsies across autoimmune diseases
- Comparison of B-cell dynamics in lupus, rheumatoid arthritis, and Sjögren’s disease, including B-cell phenotyping and the impact of prior therapies
- CD19 T-cell engager development: expectations for detecting immune reset during dose escalation and the potential implications for Phase 2 dose and schedule selection
- B cell depletion and reconstitution following dual CD19/BCMA CART targeting in SLE/LN
- Phenotypes of B cells pre-treatment and post-reconstitution
- Potential comparison to other B cell targeting therapies
